One of the most significant opportunistic parasites causing serious infections in humans is
Toxoplasma gondii (T. gondii). Lack of maximally effective therapeutic drugs for chronic toxoplasmosis
necessitates the search for a reliable and safe toxoplasmosis therapy. This study
evaluated, compared, and contrasts the curative and preventative effects of probiotics on mice
infected with the ME49 strain of T. gondii, as well as to contrast these effects with those of
spiramycin. Probiotic effects were assessed using research in parasitology, histopathology,
immunology, and immunohistochemistry. The results showed that probiotics were more helpful
when administered as a preventative measure than when provided as a treatment for toxoplasmosis.
Toxoplasma gondii cyst counts in the brain were successfully decreased by probiotics.
The inflammation in the heart, eyes, and brain also lessened as a result. Besides, it led to
a rise in interleukin-10 (IL-10) and a fall in Interferon-gamma (IFN-γ) serum levels. In the
brain, heart, and eyes, it also reduced the expression of cluster of differentiation 3 (CD3) and
Caspase3. It was less effective than spiramycin, nevertheless, as a therapy